The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Allergy/Immunology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Tue, 21 Jul 2026 11:51:26 GMT 2026 NEJM Group en-us 1440 In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks. https://www.nejm.org/doi/full/10.1056/NEJMoa2516150?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2516150 Richard A. Furie, Maria Dall’Era, Edward M. Vital, Jay P. Garg, Fedra Irazoque Palazuelos, Adolfina E. Zuta Santillán, Jorge Ravelo-Hernández, Mittermayer B. Santiago, Beatriz Zazueta Montiel, Stella Botha, Piotr Leszczyński, Viviane Angelina de Souza, Sandra A. Sicsik, Luis Bellatin, Asokan Naidoo, Zahir Amoura, Maria Antonietta D’Agostino, Sunil Kumar, Biruh Workeneh, Julie Rae, Huiyan A. Mao, Felix Erblang, Oliver Meier, Justine C. Maller, Anca D. Askanase, the ALLEGORY Trial Investigators* 2026-07-16 Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus A 38-year-old man was evaluated at the hospital because of postprandial abdominal pain. Six weeks earlier, a diarrheal illness had developed while he was working in Madagascar. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2513544?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2513544 Aima A. Ahonkhai, Howard M. Heller, Sarah M. Schrader 2026-07-16 Case 20-2026: A 38-Year-Old Man with Abdominal Pain Recombinant DNASE1L3 therapy reduced symptoms in a patient with severe lupus with DNASE1L3 deficiency. Antidrug antibodies caused effects to wane, but findings support NET-targeted therapy as a nonimmunosuppressive approach. https://www.nejm.org/doi/full/10.1056/NEJMc2601997?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2601997 Tadej Avčin, Andreas Reiff, Maša Bizjak, Barbara Jenko Bizjan, Tina Vesel Tajnšek, Maruša Debeljak, Tyler Artner, Bernd Jilma, Christian Lood, Abdul Hakkim, Tobias A. Fuchs 2026-07-16 Targeted Degradation of NETs in Lupus with DNASE1L3 Deficiency This review summarizes platelet-activating anti–platelet factor 4 disorders, including heparin-induced thrombocytopenia and related syndromes, highlighting diagnosis, antibody mechanisms, and treatment strategies. https://www.nejm.org/doi/full/10.1056/NEJMra2502459?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2502459 Theodore E. Warkentin, Andreas Greinacher 2026-07-13 Platelet-Activating Anti–Platelet Factor 4 Disorders A patient with type 1 diabetes received genetically modified allogeneic islets and no immunosuppression. Results obtained through 14 months support β-cell function and a lack of immune response against the allograft. https://www.nejm.org/doi/full/10.1056/NEJMc2604408?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2604408 Per-Ola Carlsson, Xiaomeng Hu, Hanne Scholz, Torbjörn Lundgren, Sofie Ingvast, Tim Scholz, Olof Eriksson, Per Liss, Irina Velikyan, Di Yu, Grigol Tediashvili, Tobias Deuse, Olle Korsgren, Sonja Schrepfer 2026-07-10 Long-Term Survival of Hypoimmune Allogeneic Islets without Immunosuppression During the acute phase of critical illness, early restrictive-dose enteral nutrition is preferred over parenteral nutrition to support gut integrity. Full-dose enteral nutrition increases the risk of adverse effects. https://www.nejm.org/doi/full/10.1056/NEJMra2506111?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2506111 Jayshil J. Patel, Stephen A. McClave 2026-07-09 Nutrition Therapy in Critically Ill Adults Among patients with newly diagnosed relapsing multiple sclerosis, rituximab was noninferior to ocrelizumab in preventing new or enlarging lesions on MRI. The risk of serious adverse events was similar in the two groups. https://www.nejm.org/doi/full/10.1056/NEJMoa2600993?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600993 Øivind Torkildsen, Hilde Kjelgaard Brustad, Einar August Høgestøl, Karl Bjørnar Alstadhaug, Alok Bhan, Heidi Øyen Flemmen, Andrea Habbestad, Rune A.A. Høglund, Marissa LeBlanc, Peter Lopen, Åslaug Rudjord Lorentzen, Åse Hagen Morsund, Andreas Lossius, Rigmor Lundby, Gro O. Nygaard, Brit Ellen Rød, Cecilia Smith Simonsen, Linn Steffensen, Hilde Torgauten, Fredrik Piehl, Stig Wergeland, Kjell-Morten Myhr, the OVERLORD-MS Investigators* 2026-07-02 Rituximab versus Ocrelizumab in Newly Diagnosed Relapsing Multiple Sclerosis This review summarizes advances in the treatment of multiple sclerosis, with emphasis on effective disease-modifying therapies for relapsing disease and the need for better treatments to prevent progression and rebuild myelin. https://www.nejm.org/doi/full/10.1056/NEJMra2501195?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2501195 Stephen L. Hauser 2026-07-02 Advances in Multiple Sclerosis A patient with WHIM syndrome, caused by CXCR4 chemokine receptor hyperactivity, had sustained remission after splenic rupture. A somatic mutation produced CXCR4 haploinsufficiency, suggesting allele silencing as a therapeutic strategy. https://www.nejm.org/doi/full/10.1056/NEJMc2602051?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMc2602051 David H. McDermott, Rafael Calderon-Perez, Zach Ormiston, Abigail Salancy, Bryce A. Seifert, Rachel G. Moses, Douglas B. Kuhns, Stephen M. Hewitt, David Morris, Elena Cho, Daniel Velez, Priscilla E. Quackenbush, Magdalena Walkiewicz-Yvon, Sergio M. Pontejo, Ji-Liang Gao, Philip M. Murphy 2026-07-02 Somatic Genetic Rescue of Immunodeficiency in WHIM Syndrome Peanuts should be introduced at 4 to 6 months of age in infants at high risk for allergy and at approximately 6 months of age in other infants. For infants with peanut allergy, early immunotherapy is safer and more effective. https://www.nejm.org/doi/full/10.1056/NEJMcp2314424?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2314424 George Du Toit, Gideon Lack 2026-06-25 Prevention and Treatment of Peanut Allergy Many countries rely on air-quality indices to inform the public and help protect people during short-term increases in air pollution. Their use has important societal and economic implications. https://www.nejm.org/doi/full/10.1056/NEJMp2601256?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601256 Robert D. Brook, Sanjay Rajagopalan 2026-06-25 Improving Global Air-Quality Indices — The WHO’s New Roadmap The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences. https://www.nejm.org/doi/full/10.1056/NEJMp2601300?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2601300 Arianne Teherani, Rupa Basu, Sheri Weiser 2026-06-25 When Health Costs No Longer Count — Air Pollution and EPA Rulemaking The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect. https://www.nejm.org/doi/full/10.1056/NEJMcibr2601002?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcibr2601002 Richard S. Hotchkiss, John F. DiPersio 2026-06-18 Stemness as the Engine of Checkpoint Durability In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2600931?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600931 Danny M. Cohn, Padmalal Gurugama, Hilary J. Longhurst, Emel Aygören-Pürsün, Timothy J. Craig, Henriette Farkas, Joshua Jacobs, William R. Lumry, Markus Magerl, Jonny Peter, Marc A. Riedl, David Maag, Adele Golden, Mrinal Y. Shah, Andrea Sutherland, Catherine R. Miller, Ahmed M. Abdelhady, Yuanxin Xu, James S. Butler, David Lebwohl, John Leonard, Aleena Banerji, the HAELO Investigators* 2026-06-13 Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema Neutralizing interleukin-10 autoantibodies were found in a subgroup of patients with inflammatory bowel disease and in no controls without IBD. Seropositivity was strongly associated with the IBD HLA-DRB1*01:03 risk allele. https://www.nejm.org/doi/full/10.1056/NEJMoa2513654?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513654 Nima Gharahdaghi, Pai-Jui Yeh, Lourdes Ceron-Gutierrez, Helen Griffin, Hannah Gordon, Chamara Jayamanne, Alice Fracchia, Amanda Y. Chong, Alissa Walsh, Oliver Brain, Katherine Baker, Hannah Kockelbergh, Yang Luo, Martha Guevara Becerra, Katherine Vadakethala, Madeleine Coy, Ladan Kabiri, Martin Barnardo, Susanna Dunachie, Barbara Kronsteiner, Anna Adams, Darren Fowler, Qian Zhang, Laura Fachal, Carl A. Anderson, Rofaida Desoki, Marie Vibeke Vestergaard, Lone Larsen, Nicola J. Wyatt, Robert D. Lees, Robert J. Mulligan, Chaonan Dong, Mohmmed Tauseef Sharip, Siân E. Faustini, Adrian Shields, Julia Pakpoor, Bushra Naz, Alex Richter, Jack Satsangi, Christopher A. Lamb, Miles Parkes, Fiona Powrie, Alexander J. Mentzer, Aleksejs Sazonovs, Tine Jess, Paul Klenerman, Simon Travis, Sophie Hambleton, Rainer Doffinger, Holm H. Uhlig 2026-06-11 Interleukin-10 Autoantibodies and HLA-DRB1*01:03 in Inflammatory Bowel Disease The authors describe the scientific foundations of a study implicating autoantibodies against interleukin-10 in persons with inflammatory bowel disease. https://www.nejm.org/doi/full/10.1056/NEJMe2603635?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2603635 Paul Bastard, Jean-Laurent Casanova 2026-06-11 Science behind the Study: Autoantibodies against Cytokines — From Infection to Inflammation In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. https://www.nejm.org/doi/full/10.1056/NEJMoa2602678?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2602678 Fernando C. Fervenza, Fan Fan Hou, Chuan-Ming Hao, Gianna M. Kirsztajn, Loreto Gesualdo, Tomasz Hryszko, Antonio Pisani, Dario Roccatello, Andrew S. Bomback, Julie Rae, Farima Barmaki, Eriola Berisha, Thomas Schindler, Theodore A. Omachi, Jay P. Garg, Ana Malvar, the MAJESTY Trial Investigators* 2026-06-05 Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy HLA sensitization poses major challenges to kidney transplantation. This report describes transplantation in two highly sensitized candidates after desensitization with dual CAR T-cell therapy. https://www.nejm.org/doi/full/10.1056/NEJMoa2513428?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513428 Vijay G. Bhoj, Mary Kaminski, Huiwu Zhao, Kyle Jackson, Wei Wang, Chengyang Liu, Robert A. Montgomery, Nicole Ali, Massimo Mangiola, Thomas R. Spitzer, Kassem Safa, Vikram Pattanayak, Raeda Taj, Joy Chiu, Thanh-Mai Bui, Elizabeth M. Sonnenberg, James F. Markmann, Michael C. Milone, Carl H. June, Don L. Siegel, Joseph A. Fraietta, Vanessa Gonzalez, Michela Locci, Matthew Palmer, Dimitri Monos, Wei-Ting Hwang, Tina Sledge, Nancy D. Bridges, Julia S. Goldstein, Jonah Odim, Stuart C. Sweet, Behdad D. Besharatian, Sabiha M. Hussain, Nicholas K. Brown, Malek Kamoun, Alfred L. Garfall, Ali Naji 2026-06-04 Brief Report: Kidney Transplantation in Two Highly Sensitized Candidates after CAR T-Cell Therapy Vaccine hesitancy is often driven by safety concerns. Clinician recommendations, presumptive communication, and empathy improve uptake; maintaining trust supports future acceptance and community protection. https://www.nejm.org/doi/full/10.1056/NEJMcp2516616?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2516616 Sean T. O’Leary, Margie Danchin 2026-06-04 Childhood Vaccine Hesitancy A 53-year-old man with Crohn’s disease and psoriasis presented with a 2-day history of headache, slurred speech, nausea, and vomiting. During the previous 2 weeks, he had had yellowing of the skin and eyes and dark urine. https://www.nejm.org/doi/full/10.1056/NEJMcps2506943?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcps2506943 Brittany B. Bromfield, Nikroo Hashemi, Mark S. Redston, Katherine H. Walker, Bruce D. Levy 2026-06-04 The Unusual Suspects